Depression trials recruiting in Alabama

All Depression trials nationally

Cities in Alabama

Recruiting trials in Alabama

• A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
  NCT03887715 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
  NCT07076407 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Alabama: Dothan, Huntsville
• A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder
  NCT06793397 · Phase: Phase 3 · Ages: 18 Years to 85 Years · Sex: All (male and female) · Alabama: Birmingham
• A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder
  NCT06696755 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Huntsville
• A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
  NCT07276997 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Dothan
• A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder
  NCT07227454 · Phase: Phase 3 · Ages: 12 Years to 17 Years · Sex: All (male and female) · Alabama: Birmingham
• ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
  NCT07284667 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Birmingham
• ALTO-207 in Adults With Treatment-resistant Depression (TRD)
  NCT07553637 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Birmingham, Dothan
• Digital Intervention for Physical Activity
  NCT07130734 · Phase: Not applicable (e.g. observational or device study) · Ages: 19 Years to 40 Years · Sex: All (male and female) · Alabama: Auburn
• Investigating Dynamic Interactions in Distributed Cognitive Control Networks
  NCT05927974 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Birmingham
• Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06966401 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Huntsville
• Low Voltage Electrical Stimulation for Depression in Parkinson's Patients
  NCT06467695 · Phase: Not applicable (e.g. observational or device study) · Ages: 19 Years to 65 Years · Sex: All (male and female) · Alabama: Mobile
• MicroRNA Correlates of Childhood Maltreatment and Suicidality
  NCT04923685 · Phase: Not specified · Ages: 18 Years to 60 Years · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
  NCT06372964 · Phase: Phase 3 · Ages: 10 Years to 17 Years · Sex: All (male and female) · Alabama: Dothan
• NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
  NCT06911112 · Phase: Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Huntsville
• Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents
  NCT05437588 · Phase: Not applicable (e.g. observational or device study) · Ages: 10 Years to 24 Years · Sex: All (male and female) · Alabama: Birmingham, Huntsville
• Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
  NCT06559306 · Phase: Phase 3 · Ages: 18 Years to 74 Years · Sex: All (male and female) · Alabama: Birmingham
• Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression
  NCT07226232 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · Alabama: Birmingham, Tuscaloosa
• RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
  NCT07002034 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · Alabama: Birmingham
• Strengthening Health and Insight in New Educators
  NCT06745934 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · Alabama: Tuscaloosa
• Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY)
  NCT06633016 · Phase: Phase 2 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Birmingham
• Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder
  NCT05850689 · Phase: Phase 3 · Ages: 18 Years to 65 Years · Sex: All (male and female) · Alabama: Huntsville
• Transforming Care for Individuals With Childhood-onset Systemic Lupus Erythematosus
  NCT06232304 · Phase: Not applicable (e.g. observational or device study) · Ages: 12 Years to 22 Years · Sex: All (male and female) · Alabama: Birmingham
• Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)
  NCT06423430 · Phase: Not applicable (e.g. observational or device study) · Ages: 22 Years to 70 Years · Sex: All (male and female) · Alabama: Birmingham
• Using TMS to Understand Neural Processes of Social Motivation
  NCT06274112 · Phase: Not applicable (e.g. observational or device study) · Ages: 25 Years to 50 Years · Sex: All (male and female) · Alabama: Auburn
• Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
  NCT06547489 · Phase: Phase 2 · Ages: 18 Years to 64 Years · Sex: All (male and female) · Alabama: Birmingham, Huntsville